Comparing Different Diameter fURSs With Similar RESDs for the Treatment of Upper Urinary Tract Stones
Launched by NINGBO NO. 1 HOSPITAL · May 22, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at different types of flexible ureteroscopes, which are tools used to treat kidney stones, to see which one works best. The study will compare how effective and safe these tools are when used to break up stones in the upper urinary tract, which includes the kidneys and ureters. It is currently recruiting participants aged between 18 and 80 who have kidney stones or stones in the upper ureter that are smaller than 3 cm in size.
To join the study, participants should not have certain medical conditions, such as previous surgeries on the ureters or significant kidney problems, and they must be able to understand the study details and provide consent. If eligible, participants can expect to undergo a procedure where a laser is used to break the stones, and they will be monitored for safety and effectiveness afterward. This trial is important as it aims to find the best tools for treating kidney stones, which could lead to better outcomes for patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - 1.Patients with kidney stones or upper ureteral stones with a cumulative diameter of less than 3 cm are selected for ureteral soft lens holmium laser lithotripsy.
- • 2.Age 18 to 80 years old, gender unlimited. 3.The subjects have no mental illness or language dysfunction, can understand the situation of the study and can sign informed consent.
- Exclusion Criteria:
- • 1.Patients with a history of ureteral stenosis or who have undergone open or laparoscopic ureteral or renal lithotomy.
- • 2.Patients with fever one week before surgery 3.Pregnant women and menstruating patients. 4.Patients with combined systemic disease or inability to tolerate anesthesia. 5.Patients undergoing simultaneous surgery for bilateral upper urinary tract stones.
- • 6.Patients with ureteral stent indwelling before surgery. 7.In patients with severe hydronephrosis, the separation of the renal collecting system is greater than 4 cm.
- • 8.Patients with renal anatomic malformations such as polycystic kidney, horseshoe kidney, and ectopic kidney.
About Ningbo No. 1 Hospital
Ningbo No. 1 Hospital is a leading medical institution located in Ningbo, China, dedicated to advancing healthcare through innovative clinical research and trials. With a strong emphasis on patient-centered care, the hospital is equipped with state-of-the-art facilities and a multidisciplinary team of experienced professionals. As a clinical trial sponsor, Ningbo No. 1 Hospital aims to contribute to the development of new therapies and treatment protocols, ensuring the highest standards of safety and efficacy while fostering collaboration with national and international research organizations. Their commitment to excellence in clinical research underpins their mission to enhance patient outcomes and promote medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ningbo, Zhejiang, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported